A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989

被引:23
作者
Atkinson, K [1 ]
Nivison-Smith, I [1 ]
Dodds, A [1 ]
Concannon, A [1 ]
Milliken, S [1 ]
Downs, K [1 ]
机构
[1] St Vincents Hosp, Dept Hematol, Sydney, NSW 2010, Australia
关键词
cytomegalovirus; interstitial pneumonitis; ganciclovir; marrow allograft;
D O I
10.1038/sj.bmt.1701145
中图分类号
Q6 [生物物理学];
学科分类号
071011 [生物物理学];
摘要
A comparison was made of the pattern of interstitial pneumonitis (IF) following allogeneic bone marrow transplantation before and after the introduction of ganciclovir prophylaxis to minimize the risk of cytomegalovirus (CMV) disease in the St Vincent's Hospital bone marrow transplant program in 1989. A total of 456 recipients of allogeneic transplants were included, 280 received no prophylactic ganciclovir while 176 received prophylactic ganciclovir. The overall incidence of interstitial pneumonitis dropped from 19.6 to 12.5% (P = 0.03) and this was primarily due to a reduction in the incidence of CMV-LP which fell from 12.9 to 1.7% (P < 0.0005). The incidence of idiopathic IP was not different between the two groups (6.3 vs 3.2 %), nor was the incidence of Pneumocystis carinii pneumonia (2.9 and 0.6%), Prophylactic ganciclovir has thus had a significant impact in reducing both the overall incidence of IP and specifically cytomegalovirus IP in allogeneic marrow transplant recipients, The most common form of IP in patients given prophylactic ganciclovir is now idiopathic interstitial pneumonitis.
引用
收藏
页码:691 / 695
页数:5
相关论文
共 11 条
[1]
ATKINSON K, 1991, BONE MARROW TRANSPL, V8, P231
[2]
PROPHYLACTIC USE OF GANCICLOVIR IN ALLOGENEIC BONE-MARROW TRANSPLANTATION - ABSENCE OF CLINICAL CYTOMEGALOVIRUS-INFECTION [J].
ATKINSON, K ;
DOWNS, K ;
GOLENIA, M ;
BIGGS, J ;
MARSHALL, G ;
DODDS, A ;
CONCANNON, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (01) :57-62
[3]
A PROSPECTIVE RANDOMIZED TRIAL OF CYCLOSPORIN VERSUS METHOTREXATE AFTER HLA-IDENTICAL SIBLING MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE-LEUKEMIA IN 1ST REMISSION - ANALYSIS 2.5 YEARS AFTER LAST PATIENT ENTRY [J].
ATKINSON, K ;
BIGGS, JC ;
CONCANNON, A ;
DODDS, A ;
DOWNS, K ;
ASHBY, M .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1988, 18 (04) :594-599
[4]
ATKINSON K, 1987, BONE MARROW TRANSPL, V2, P358
[5]
CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[6]
GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178
[7]
THE EFFECT OF GRANULOCYTE TRANSFUSIONS ON THE INCIDENCE OF CYTOMEGALOVIRUS-INFECTION AFTER ALLOGENEIC MARROW TRANSPLANTATION [J].
HERSMAN, J ;
MEYERS, JD ;
THOMAS, ED ;
BUCKNER, CD ;
CLIFT, R .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (02) :149-152
[8]
KAPLAN EL, 1958, J AM STAT ASSOC, V35, P347
[9]
LERNER KG, 1974, TRANSPLANT P, V6, P367
[10]
RISK-FACTORS FOR CYTOMEGALOVIRUS-INFECTION AFTER HUMAN MARROW TRANSPLANTATION [J].
MEYERS, JD ;
FLOURNOY, N ;
THOMAS, ED .
JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (03) :478-488